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general hospital (PB 6M€ ). We chose 24 active ingredients (95 different antibiotics) 
that represent about 1/3 of total hospital antibiotics and 80% of the total anti-
biotics’ budget. We studied their consumption for the years 2011 and 2012 and 
calculated the costs based on the official drug pricelist and their price after the 
negotiation. Results: From 2011 to 2012 the discounts gained from each hospital 
were increased. Price negotiation does not apply in prototype drugs that their com-
panies are only obliged to offer a 5% rebate. Unfortunately, these medications are 
more expensive, represent 36% of the studied antibiotics’ cost and their consump-
tion was increased by 20%. But, the discounts for all the studied off-patent drugs 
and their generics were from 12.8% till 89.9%. Thus, the total cost saving for them 
was 33.2% at PAGNI, 26.0% at Evaggelismos and 43.1% at Tzaneio. The total benefit 
for the pharmaceutical expenditure was 3% for both PAGNI and Evaggelismos, and 
6% for Tzaneio. ConClusions: Price negotiation is an effective mean of decreas-
ing the cost of off-patent and generic drugs but newer and expensive drugs get 
doctors’ preference, undermining the Pharmacy’s cost-saving effort.
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objeCtives: To estimate the costs and benefits of patient pathways incorporating 
a point of care nucleic acid amplification test (POC NAAT) for chlamydia and gonor-
rhoea in genito-urinary medicine (GUM) clinics in the UK compared with standard 
off-site laboratory testing. Methods: We simulated 1.2 million men and women 
GUM clinic attendees based on GUMCAD reports from the UK (2011). A Markov 
model with Monte Carlo simulation in Microsoft Excel was developed to compare 
existing standard pathways of testing and treatment for chlamydia and gonorrhoea 
with a POC NAAT. We conducted sensitivity analyses to evaluate the robustness of 
the model findings. The primary outcome was the incremental cost-effectiveness 
ratio (ICER = £/QALY). Secondary outcomes included the number of inappropriate 
treatments, complications and transmissions averted and change in time from test 
to treatment. Results: The total cost of using the POCT in our cohort was £103.3 
million compared with £113.9 million for standard care. The ICER was -£4,182/QALY, 
making the new pathways cost saving. Nearly 100,000 inappropriate treatments 
might be avoided by using a POC NAAT. Patients receive diagnosis and treatment on 
the same day as testing, which may also prevent 162 cases of pelvic inflammatory 
disease and 17,561 transmissions. ConClusions: Replacing standard laboratory 
tests for chlamydia and gonorrhoea with a POCT could be cost saving and patients 
would benefit from more accurate diagnosis and less unnecessary treatment. 
Overtreatment currently accounts for about a tenth of the reported treatments for 
chlamydia and gonorrhoea and POC NAATs would effectively eliminate the need 
for presumptive treatment.
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objeCtives: Rotavirus (RV) causes highly contagious gastroenteritis especially in 
children under five years of age. Since 2006, two RV-vaccines are available in Europe 
(Rotarix® and RotaTeq®). We evaluated the cost-effectiveness of these vaccines for 
the German health care setting, inter alia to support an informed decision-making 
concerning a potential vaccination-recommendation. Methods: A Markov Model 
was developed to evaluate the cost-effectiveness from the statutory health insur-
ance (SHI) (direct costs) and from the societal perspective (SHI plus indirect costs). 
Health outcomes considered were RV-cases prevented, RV-associated hospitalizations 
avoided, and quality-adjusted life-years (QALY) gained. RV-incidences were derived 
from the national mandatory disease reporting system. RV-vaccine efficacy was cal-
culated as pooled estimates based on data from randomized controlled trials. Costs 
(reference year 2010) were derived from official price catalogues. An annual discount 
rate of 3% for effects and costs was applied. The first five life-years were considered as 
model’s time horizon. Results: The base-case analysis (SHI-perspective) resulted in 
an incremental cost-effectiveness and cost-utility ratio (ICER) for Rotarix® of € 184 per 
RV-case prevented, € 2,457 per RV-associated hospitalization avoided, and € 116,973 
per QALY gained. For RotaTeq®, the results were slightly higher (€ 234, € 2,622, and € 
142,732, respectively). In sensitivity analyses parameter variation showed effects on 
the ICERs without changing the overall trend. A threshold analysis suggests that cost-
saving scenarios are possible with vaccine prices reduced by ~62-66%. When applying 
base-case scenario results to the 2012 birth-cohort with 80% vaccination coverage, an 
estimated 206,000-242,000 RV-cases and 18,000 RV-associated hospitalizations can be 
prevented in this birth-cohort over 5 years for an incremental cost of 44.5-48.2 million 
Euros. ConClusions: Routine RV-vaccination is expected to prevent a consider-
able number of RV-cases and RV-associated hospitalizations in Germany. Though, the 
amount of QALYs gained is low. With current vaccine prices, RV-vaccination is not a 
cost-saving preventive measure.
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boceprevir. Total costs of AE and discontinuation were $10,443 and $3,736 for telaprevir 
and boceprevir treated groups, respectively. The results were not sensitive to variation 
in treatment practices and costs. ConClusions: The costs of treatment of cirrhotic 
non-responders during the first 16 weeks were estimated to increase by 18% over triple 
therapy costs due to AEs. These data indicate that the total cost per cure may be sub-
stantially higher than the drug costs and underscore the importance of evaluating total 
cost of HCV treatment when selecting new agents.
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objeCtives: Current guidelines for the treatment of acute bacterial skin and skin 
structure infections (ABSSSI) recommend several treatment pathways based on the 
infection types and severity. The objective of this study is to establish the health 
care resource utilization (HRU) and costs associated with the most common patient 
treatment pathways in US. Methods: The medical and pharmacy administrative 
claims of adult ABSSSI patients with continuous commercial or Medicare Advantage 
enrollment with Part D prescription drug coverage between 01 January 2009 and 
31 December 2011 were extracted from a large national health plan affiliated with 
OptumInsight. The four most common treatment pathways were identified based on 
the evidences of antibiotics over the entire ABSSSI treatment course. All four path-
ways start with vancomycin IV use during a hospital stay. At discharge, patients fol-
lowed one of four pathways: 1) continue IV vancomycin as an Outpatient Parenteral 
Antibiotic Therapy (OPAT); 2) switch to oral linezolid; 3) switch to daptomycin; or 4) 
switch to any oral antibiotic other than linezolid, clindamycin, or TMP-SMX. Health 
care resource utilization and costs were determined for each pathway. Results: A 
total of 1418 patients met all of inclusion/exclusion criteria. The majority of patients 
either continued Vancomycin IV (46.5%) or switched to oral linezolid (41.4%) at dis-
charge. Only about 12% of patients were switched to Daptomycin or other non-MRSA 
active oral antibiotics. The average ABSSSI-related total health care cost was $16,571 
for the entire ABSSSI treatment. Total costs were comprised of $12,519 (75.5%) for 
inpatient cost, $201 (1.2%) for emergency department (ED) visits, $879 (5.3%) for 
outpatient treatment/office visits, and $1,015(6.1%) for pharmacy claims cost. The 
costs overall and in various locations of care varied by pathway. ConClusions: 
Inpatient treatment remains the largest component of total ABSSSI treatment cost. 
Utilization of linezolid and daptomycin increased the pharmacy or OPAT costs.
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objeCtives: To examine the economic burden and health care utilizations 
of patients diagnosed with the hepatitis B virus (HBV) in the U.S. veteran 
population. Methods: A retrospective database analysis was performed using the 
Veterans Health Administration (VHA) Medical SAS datasets from October 1, 2008 to 
September 30, 2012. Patients diagnosed with HBV were identified using International 
Classification of Disease 9th Revision Clinical Modification (ICD-9-CM 070.22, 070.23, 
070.32, 070.33, V02,61) diagnosis codes. The first diagnosis date was defined as the 
index date. A group of patients of the same age, region, gender and index year but 
without HBV infection were identified and matched by baseline Charlson Comorbidity 
Index (CCI) as the comparison group. A 1-year continuous health plan enrollment was 
required before and after the index date for both groups. Study outcomes, including 
health care costs and utilizations, were compared between the HBV and compara-
tor groups using 1:1 propensity score matching. Results: A total of 9,718 patients 
were identified for the HBV and comparison cohorts. After applying a 1:1 matching, 
a total of 3,093 patients were matched from each cohort, and the baseline character-
istics were proportionate. Patients diagnosed with HBV infection were more likely to 
report higher health care utilizations, including inpatient (28.74% vs. 3.3%, p< 0.01), 
emergency room (25.67% vs. 8.3%, p< 0.01), physician office (98.60% vs. 62.75%) and 
pharmacy visits (88.23% vs. 63.65%, p< 0.01). The risk-adjusted health care costs were 
also higher for patients infected with HBV due to increased inpatient ($10,481 vs. $804, 
p< 0.01), emergency room ($382 vs. $80, p< 0.01), physician office ($4,635 vs. $1,678, 
p< 0.01), and pharmacy visits ($1,166 vs. $398, p< 0.01) resulting in higher total costs 
($16,909 vs. $3,045, p< 0.01) relative to the comparator cohort. ConClusions: During 
a period of 12 months, VHA patients diagnosed with HBV reported higher health care 
utilization and costs than their matched controls.
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objeCtives: Since Greece came under the regime of IMF and signed the memo-
randum, several curtailments had to be made to various areas of the public sec-
tor. Drug treatment seems to be quite expensive. As part of the strict economic 
rules, Greek hospitals were obliged to reduce their health care costs. The phar-
macy of each hospital incurred considerable weight of this attempt. One of its 
implemented actions was the drugs’ price negotiation with the pharmaceuti-
cal companies. Methods: In order to measure the effectiveness of this action, 
we performed a comparative study of the antibiotics used in 3 hospitals, PAGNI, 
Evaggelismos and Tzaneio. PAGNI and Evaggelismos are among the 5 biggest hos-
pitals of Greece (pharmaceutical budget around 40M€ ) while Tzaneio is a small 
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objeCtives: Compare the cost per cure of telaprevir of peginterferon and ribavirin 
(TVR+PR) compared to boceprevir plus peginterferon and ribavirin (BOC+PR) in 
the treatment of METAVIR scale F2 patients with previously untreated chronic 
hepatitis C genotype 1 in the Brazilian public (SUS) and private (SS) health care 
system. Methods: Treatment costs considered drug acquisition costs of TVR+PR 
and BOC+PR from a public and private payer perspective in Brazil. The cost/cure 
was defined as the cost/sustained virological response (SVR) according to the 
phase 3 trials of TVR and BOC. The SVR rate for TVR+PR was defined as 79% and 
49% for PR in patients with F2 fibrosis. Based on the SPRINT-2 trial, the SVR-rate 
for F2 patients treated with BOC+PR was assumed 57%, average between F0/F1 
and F3/F4 patients, compared to 38% for PR. Treatment duration, based on the 
extended rapid virological response (eRVR), was taken from the respective trials 
of BOC (eRVR = 44%) and TVR (eRVR = 58%). Deterministic sensitivity analysis 
was carried out for the eRVR rate. Results: In the SUS, TVR+PR had an average 
treatment cost of R$ 40.093 per F2 fibrosis patient compared to R$ 36.185 with 
BOC+PR. Considering the SVR rate and the sensitivity analysis, TVR+PR had a 
cost/SVR of R$ 50.751 (R$ 49.797-R$ 51.705) compared to R$ 63.481 (R$ 61.771-R$ 
65.191) with BOC+PR. In the private health care system, TVR+PR had a treatment 
cost of R$ R$ 88.508 per F2 fibrosis patient compared to R$ 82.518 with BOC+PR. 
Considering the cost/SVR and sensitivity analysis, TVR+PR had a cost/SVR of R$ 
112.036 (R$ 108.253-R$ 115.819) compared to BOC+PR with a cost/SVR of R$ 144.768 
(R$ 140.631-R$ 148.905) per F2 patient in the SS. ConClusions: Compared to 
BOC+PR, TVR+PR was a more cost-effective treatment of F2 fibrosis patients in 
both public and private health care systems.
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treatmeNt of ChIldreN aNd yoUNg PeoPle WIth ChroNIC hePatItIs C 
from the PersPeCtIve of the Nhs IN eNglaNd aNd Wales
Lion M.1, McCann E.1, Jiang Y.2
1MSD Ltd., Hoddesdon, UK, 2Amaris, London, UK
objeCtives: To evaluate the cost-effectiveness of peginterferon (PEG INF) alfa and riba-
virin for the treatment of children and young people ages 3 to 17 years with Chronic 
Hepatitis C (CHC), from the perspective of the NHS in England and Wales. This analysis 
was submitted to NICE as part of a submission dossier for the multiple technology 
appraisal of PEG INF alfa and ribavirin for the respective population. Methods: A 
Markov model was developed based on previous economic evaluations for treatment 
of adults with CHC with PEG INF alfa and ribavirin. The model evaluated the cost-effec-
tiveness of PEG INF alfa-2a or alfa-2b and ribavirin, and supportive care, for the treatment 
of people aged 5 to 17 years. An additional analysis was conducted on 3 and 4 year olds 
comparing supportive care to PEG INF alfa-2b and ribavirin in line with license. The 
cost-effectiveness was evaluated using the incremental cost-effectiveness ratio (ICER) 
from the perspective of the NHS over a lifetime horizon. The results were assessed 
overall and by age and genotype subgroups. Results: The results reported that both 
combinations of PEG INF alfa and ribavirin dominated supportive care for all patients. 
Driven by small variation in the comparative efficacy and costs, the comparison between 
PEG INF alfa-2a and alfa-2b, in combination with ribavirin, showed that PEG INF alfa-2b 
dominated PEG INF alfa-2a overall and in the following subgroups: 5 to 8 years, 14 to17 
years and genotypes 2/3. The ICER for the 9 to13 years subgroup was £4,697. PEG INF 
alfa-2a dominated PEG INF alfa-2b for the other genotype subgroup ConClusions: The 
results of the economic evaluation demonstrated that treatment with either combina-
tion of PEG INF alfa and ribavirin is a cost-effective treatment option for children and 
young people aged 3 to 17 years with CHC.
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objeCtives: Streptococcus pneumoniae is presumed to be the major etiology 
agent responsible for a significant amount of meningitis, bacteremia and sepsis 
(invasive pneumococcal disease; IPD) as well as Community Acquired Pneumonia 
(CAP) and Acute Otitis Media (AOM). The Czech Republic (CR), as well as many 
other European countries have only a limited local evidence on the underlying 
epidemiology. The objective was to estimate the expected outcomes, costs, cost-
effectiveness of the pediatric national immunization program (NIP) with 13-valent 
pneumococcal conjugated vaccine (PCV13) and 10-valent pneumococcal conju-
gated vaccine (PCV10) as a comparator among specific populations of children 
and adults in preventing and reducing the incidence of IPD, CAP and AOM in 
CR. Methods: A Markov decision-analytic model was developed to examine 
impacts of infant vaccination with PCV13 versus PCV10. PCV13 direct effectiveness 
was extrapolated from PCV7 efficacy data from clinical trials, using assumptions 
regarding serotype prevalence and PCV13 protection against additional serotypes, 
while indirect (herd) effect was extrapolated from US surveillance data following 
universal PCV7 use. The local epidemiology and cost data were used to achieve 
maximum national specificity. Results: Model predicts incremental EUR 64.5 
million for the PCV13 NIP from the payer’s perspective in the 10-year horizon, as 
compared to PCV10. This would lead to an reduction in IPD, all cause inpatient and 
outpatient CAP and AOM by approximately 921, 22 900, 56 796 and 40 598 cases, 
respectively, thus savings EUR 35.4 million. This gives a total cost of EUR 29.0 mil-
lion in the 10 years. The incremental cost per LYG or QALY gained is estimated 
as EUR 929 or EUR 1 164, respectively, from the payer’s perspective as compared 
to PCV10. ConClusions: Comparing the national GDP per capita with the WHO 
objeCtives: To estimate the cost-effectiveness (CE) of the 3 echinocandins 
(Anidulafungin, Caspofungin and Micafungin) and generic Fluconazole in the treatment 
of adult non-neutropaenic patients with invasive candidiasis (IC) in a Spanish Intensive 
Care Unit (ICU) setting. Methods: A 4 arm decision tree model was developed with the 
3 echinocandins and generic Fluconazole as first line treatment. In case of treatment 
failure, a 2nd line treatment was administered (Liposomal Amphotericin-B following 
the echinocandins and either one of the 3 echinocandins for Fluconazole arm). After 2nd 
line failure, treatment was discontinued. Total treatment length was 14 days. Efficacy 
and safety (adverse events/lack of efficacy) parameters where obtained from a mixed-
treatment-comparison and a meta-analysis respectively. Efficacy was considered as 
first line success (Anidulafungin 75.32%; Micafungin 71.65%; Caspofungin 70.62%; and 
Fluconazole 56.7%). Length of the first and the second line were elicited using experts’ 
opinion through Delphi methodology. Daily drug acquisition costs were considered 
only. The CE was expressed as an incremental cost-effectiveness ratio (ICER). Univariate 
sensitivity analyses were also applied and included, length of treatment in 1st or 2nd line 
and finally drug dosages calculated as per SmPC recommendations according to dif-
ferent patient characteristics. Results: Total costs of IC treatment for Anidulafungin, 
Micafungin, Caspofungin and Fluconazole were € 5,552; € 5,985; € 6,350; € 1,654 respec-
tively. Anidulafungin was dominant compared to Micafungin and Caspofungin. 
Anidulafungin and Micafungin were cost-effective (€ 20,934; 29.576€ respectively) 
compared to Fluconazole (CE threshold of € 30,000). Sensitivity analyses revealed that 
ICER was sensitive to increases in the length of the 1st and 2nd line treatments, although 
Anidulafungin was cost-effective in all scenarios. ConClusions: Based on the model’s 
assumptions, Anidulafungin is cost-saving compared to Micafungin and Caspofungin 
and cost-effective vs. Fluconazole in the treatment of patients with confirmed invasive 
candidiasis from a Spanish Hospital ICU perspective.
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objeCtives: The ventilator associated pneumonia (VAP) refers to the pneumonia 
that appears after 48-72 hours of endotracheal intubation and is the most common 
nosocomial infections in patients receiving mechanical ventilation. Late-onset VAP 
is responsible for prolonged ICU stay and higher mortality rates (24 to 50% and can 
even increase to 76%), which explains the importance of using more effective anti-
biotics depending on the severity of each case. The aim of this study is to assess 
the cost-effectiveness (CE) of linezolid against vancomycin in the treatment of VAP, 
from the public health care perspective. Methods: A cohort of patients with VAP 
was simulated using a decision-tree model to compare costs and effectiveness of 
linezolid (600 mg/12 hours) and vancomycin (1 g/12 hours). Effectiveness measures 
were: microbiological success rates, mortality rates, and ICU and ward LOS. The model 
used a 12-week time horizon and only direct medical costs were considered (inpatient 
costs, medication expenses, adverse events costs). Effectiveness and epidemiologic 
data were retrieved from published literature. Local costs (2013 US$) were gathered 
from the official databases of Jamaican Health System. Monte Carlo probabilistic 
sensitivity analysis (PSA) was constructed. Results: Linezolid resulted as the most 
effective and less expensive option for VAP adult patients. Clinical success rate was 
higher with linezolid (64.4%) against vancomicyn (56.1%). Mean expected ICU LOS 
was 14 days for linezolid and 17 days for vancomycin, ward LOS was 14 and 24 days 
with linezolid and vancomycin, respectively. Mortality rate was found lower in the 
linezolid arm (10.13%) in comparison to vancomycin (15.74%). Overall costs per patient 
were $36721.65 with linezolid and $40776.82 with vancomycin. In the CE incremental 
analysis, linezolid appeared as the cost-saving option. PSA outcomes support the 
robustness of these findings. ConClusions: Linezolid resulted as the cost-saving 
therapy for treating VAP adult patients in Jamaica.
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objeCtives: Boceprevir plus P/R has demonstrated a superior clinical profile, com-
pared to P/R alone, in the treatment of genotype 1 chronic hepatitis C (G1-CHC) 
patients. The objective of this study was to evaluate the cost-effectiveness of 
BOC/P/R therapy for treatment naïve and treatment experienced G1-CHC patients 
in Greece. Methods: A Markov-model simulating the quality-adjusted life years 
and corresponding costs of G1-CHC treatment provided the basis of the analyses. 
The BOC/P/R regimens recommended in the label for treatment naïve and treat-
ment experienced patients were compared to P/R to calculate incremental costs and 
outcomes. The inputs for the model were derived from post-hoc subset analyses of 
SPRINT-2 and RESPOND-2 data. Resource use for patient monitoring and treatment 
of events was elicited via expert panel. Lifetime horizon with 3% discount rate was 
used and the perspective of analysis was third-party payers. Results: BOC-based 
therapy was projected to reduce liver complications (decompensated cirrhosis, hepa-
tocellular carcinoma, liver transplant and liver–related death) by 44% and 49-53% 
in treatment naïve and experienced patients, respectively, leading to correspond-
ing gains of 0.87 and 1.25 QALYs per patient. Taking into account medication costs, 
treatment and management of events, the ICER for BOC-based therapy versus P/R 
were estimated at 10,003€ /QALY and 10,852€ /QALY for treatment naïve and expe-
rienced patients, respectively. Extensive sensitivity analyses indicated that results 
were robust. ConClusions: Based on the results of this analysis, the addition of 
Boceprevir to P/R for treatment of G1 CHC patients can be a cost-effective treatment 
option in the Greek health care setting.
